

HOLLIS EDEN PHARMACEUTICALS INC /DE/
Form 8-K
August 12, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2003

HOLLIS-EDEN PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

000-24672

(Commission File No.)

Delaware
(State or other

jurisdiction of incorporation)

13-3697002
(IRS Employer

Identification No.)

4435 Eastgate Mall, Suite 400

San Diego, California 92121

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: (858) 587-9333

ITEM 5. OTHER EVENTS.

On August 11, 2003, Hollis-Eden Pharmaceuticals, Inc., a Delaware corporation (Hollis-Eden), issued a press release announcing the conversion of all of its outstanding convertible debentures into 1,675,581 shares of Hollis-Eden common stock, including accrued interest. See Exhibit 99.1 for the text of the press release.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.

EXHIBITS.

99.1 Press release issued on August 11, 2003 by Hollis-Eden.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HOLLIS-EDEN PHARMACEUTICALS, INC.

Dated: August 11, 2003

By:

/s/ ERIC J. LOUMEAU

Eric J. Loumeau

Vice President, General Counsel

INDEX TO EXHIBITS

99.1 Press Release issued on August 11, 2003 by Hollis-Eden Pharmaceuticals, Inc.